Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Other Non-Current Liabilities (2018 - 2025)

Medicinova has reported Other Non-Current Liabilities over the past 6 years, most recently at $17129.0 for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 91.9% to $17129.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17129.0 through Dec 2025, down 91.9% year-over-year, with the annual reading at $17129.0 for FY2025, 91.9% down from the prior year.
  • Other Non-Current Liabilities was $17129.0 for Q4 2025 at Medicinova, down from $74399.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $737716.0 in Q3 2021 and troughed at $2211.0 in Q1 2021.
  • The 5-year median for Other Non-Current Liabilities is $380922.5 (2023), against an average of $359947.2.
  • Year-over-year, Other Non-Current Liabilities surged 28523.65% in 2022 and then plummeted 91.9% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $694674.0 in 2021, then decreased by 24.62% to $523619.0 in 2022, then fell by 21.57% to $410660.0 in 2023, then crashed by 48.51% to $211460.0 in 2024, then plummeted by 91.9% to $17129.0 in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Other Non-Current Liabilities are $17129.0 (Q4 2025), $74399.0 (Q3 2025), and $117038.0 (Q2 2025).